IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
-0.52%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$449M
AUM Growth
+$449M
(+8.3%)
Cap. Flow
+$48.9M
Cap. Flow
% of AUM
10.89%
Top 10 Holdings %
Top 10 Hldgs %
46.73%
Holding
81
New
13
Increased
18
Reduced
10
Closed
8
Top Buys
| 1 |
Exelon
EXC
|
$9.99M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$9.44M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$8.99M |
| 4 |
CRISPR Therapeutics
CRSP
|
$8.19M |
| 5 |
Amgen
AMGN
|
$5.95M |
Top Sells
Sector Composition
| 1 | Healthcare | 97.48% |
| 2 | Utilities | 2.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$155B
| $32.6M | 7.26% | 144,746 +26,446 | +22% | +$5.95M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $23.8M | 5.31% | 280,000 -9,500 | -3% | -$809K |
|
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $21.7M | 4.84% | 128,000 +53,000 | +71% | +$8.99M |
|
4
Incyte
INCY
$16.5B
| $20.9M | 4.66% | 285,000 +14,640 | +5% | +$1.08M |
|
5
Gilead Sciences
GILD
$140B
| $20.5M | 4.57% | 282,784 -120,000 | -30% | -$8.71M |
|
|
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $19.3M | 4.3% | 139,900 -36,500 | -21% | -$5.03M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $18.5M | 4.13% | 126,500 +28,000 | +28% | +$4.11M |
|
8
PTC Therapeutics
PTCT
$3.92B
| $17.9M | 3.98% | 449,000 | – | – |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $17.5M | 3.89% | 113,200 +3,500 | +3% | +$540K |
|
10
Vertex Pharmaceuticals
VRTX
$100B
| $17M | 3.78% | 77,222 | – | – |
|
11
Illumina
ILMN
$15.8B
| $14.3M | 3.18% | 37,500 +10,500 | +39% | +$3.99M |
|
12
Travere Therapeutics
TVTX
$1.56B
| $11.8M | 2.63% | 380,000 | – | – |
|
13
Ultragenyx Pharmaceutical
RARE
$2.89B
| $11.6M | 2.59% | 138,100 +35,000 | +34% | +$2.94M |
|
14
Biogen
BIIB
$19.4B
| $11.4M | 2.54% | 47,500 +22,000 | +86% | +$5.28M |
|
|
15
Ionis Pharmaceuticals
IONS
$6.8B
| $10.8M | 2.41% | 355,088 +310,307 | +693% | +$9.44M |
|
|
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $10.8M | 2.4% | 99,873 -138,000 | -58% | -$14.9M |
|
17
Harmony Biosciences
HRMY
$2.12B
| $10.1M | 2.24% | 236,000 | – | – |
|
|
18
Exelon
EXC
$44.1B
| $9.99M | 2.22% | +546,534 | New | +$9.99M |
|
19
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.29M | 2.07% | 105,156 +50,000 | +91% | +$4.42M |
|
20
Supernus Pharmaceuticals
SUPN
$2.53B
| $8.68M | 1.93% | 297,500 | – | – |
|
|
21
CRISPR Therapeutics
CRSP
$4.71B
| $8.19M | 1.83% | +108,200 | New | +$8.19M |
|
22
Aurinia Pharmaceuticals
AUPH
$1.58B
| $7.65M | 1.7% | 334,500 +211,000 | +171% | +$4.82M |
|
23
Regeneron Pharmaceuticals
REGN
$61.5B
| $7.64M | 1.7% | 12,100 +4,400 | +57% | +$2.78M |
|
24
Guardant Health
GH
$8.41B
| $7.45M | 1.66% | 74,500 +38,000 | +104% | +$3.8M |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.92M | 1.32% | 113,456 +34,000 | +43% | +$1.78M |
|